礼来公司QIAGEN开发阿尔茨海默氏症风险检测测试

2024-09-05 05:28

QIAGEN (NYSE:QGEN) has entered into a collaboration with Eli Lilly (NYSE:LLY) for the development of an in vitro diagnostic to help identify patients at risk for developing Alzheimer’s disease.
The diagnostic panel would be for the detection of APOE genotypes, which can play a role in diagnosing the disease, The product would be integrated with QIAGEN’s QIAstat Dx testing platform, according to a statement.
QIAGEN (QGEN) said the panel would be able to detect all APOE genotypes, including APOE2, APOE3 and APOE4.
Lilly (LLY) markets one of the few treatments for Alzheimer’s disease, Kisunla. The product, also known as donanemab, was approved by the FDA in July.
Biogen (BIIB) and Eisai (OTCPK:ESALF)(OTCPK:ESAIY) also market a treatment for Alzheimer’s. Leqembi, also known as lecanemab, received accelerated approval by the FDA in January 2023 and full approval in July 2024.

More on Qiagen